Canada Markets open in 34 mins

Microbix Biosystems Inc. (MBX.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
0.3500-0.0050 (-1.41%)
At close: 01:30PM EST
Full screen
Previous Close0.3550
Open0.3500
Bid0.3400 x 0
Ask0.3500 x 0
Day's Range0.3300 - 0.3500
52 Week Range0.3300 - 0.6900
Volume63,000
Avg. Volume38,572
Market Cap48.647M
Beta (5Y Monthly)0.23
PE Ratio (TTM)N/A
EPS (TTM)-0.0510
Earnings DateFeb 08, 2023 - Feb 13, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateSept 02, 1999
1y Target Est1.13
  • GlobeNewswire

    Microbix Reports Results for Q1 Fiscal 2023 Sales of $2.5 million, Net Loss of $1.3 million

    MISSISSAUGA, Ontario, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its first quarter ended December 31, 2022 (“Q1”), a period in which reduced sales across two major product lines resulted in the first quarterly net loss in two years. Microbix remains well-capitalized and is targeting to continue increasing sales of its testing-related medical devices and ingredients, the

  • GlobeNewswire

    Microbix Presenting Results of Collaboration with Health PEI

    QAPs for HPV Test Verification within Cervical Cancer Screening ProgramMISSISSAUGA, Ontario, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it will be presenting results of its collaboration with the Microbiology Laboratory of the Queen Elizabeth Hospital of Health PEI (“Health PEI”), in support of provincial adoption of molecular diagnostic (“MDx”) screening for Human Papilloma

  • GlobeNewswire

    Microbix Launches QAP to Support “Monkeypox” Testing

    Driven by Customer Requests, Mpox Test Control Now AvailableMISSISSAUGA, Ontario, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it is launching a new quality assessment product (“QAP™”) to support molecular diagnostic (“MDx”) testing for the Non-Variola Orthopoxvirus (“Mpox”), the cause of the cutaneous infection colloquially-known as “Monkeypox.” From traditional low-level inc